New York Post
By Taylor Herzlich
Published Feb. 18, 2026, 9:35 a.m. ET
The Food and Drug Administration has reversed its decision not to review a new flu vaccine from Moderna, the pharmaceutical company said Wednesday.
Last week, the FDA sent a missive to Moderna refusing to review its new shot, saying its application did not contain adequate research — leaving the company’s president, Dr. Stephen Hoge, in “complete shock.”
In an exclusive interview with The Post, Hoge said he was “completely surprised and honestly pretty confused” after receiving the letter from Dr. Vinay Prasad, the FDA’s top vaccine official.
Super Sleuth
